Telmisartan mitigates lipopolysaccharide (LPS)-induced production of mucin 5AC (MUC5AC) through increasing suppressor of cytokine signaling 1 (SOCS1)

Acute lung injury (ALI) is a serious clinical pulmonary disease. The pathogenesis of ALI is related to the excessive release of inflammatory factors and upregulation of mucin 5AC (MUC5AC). Telmisartan is a novel antihypertension agent that exerts promising anti-inflammatory effects. The purpose of t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ling Chen, Jiajia Xu, Meiyu Deng, Yanling Liang, Jinfu Ma, Linghui Zhang, Yijie Wang, Jinping Zhang
Formato: article
Lenguaje:EN
Publicado: Taylor & Francis Group 2021
Materias:
Acceso en línea:https://doaj.org/article/e77a2296a10f469487182329fbab81c5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:e77a2296a10f469487182329fbab81c5
record_format dspace
spelling oai:doaj.org-article:e77a2296a10f469487182329fbab81c52021-11-04T15:51:53ZTelmisartan mitigates lipopolysaccharide (LPS)-induced production of mucin 5AC (MUC5AC) through increasing suppressor of cytokine signaling 1 (SOCS1)2165-59792165-598710.1080/21655979.2021.1943605https://doaj.org/article/e77a2296a10f469487182329fbab81c52021-01-01T00:00:00Zhttp://dx.doi.org/10.1080/21655979.2021.1943605https://doaj.org/toc/2165-5979https://doaj.org/toc/2165-5987Acute lung injury (ALI) is a serious clinical pulmonary disease. The pathogenesis of ALI is related to the excessive release of inflammatory factors and upregulation of mucin 5AC (MUC5AC). Telmisartan is a novel antihypertension agent that exerts promising anti-inflammatory effects. The purpose of this study is to investigate whether Telmisartan has a protective role in lipopolysaccharide (LPS)-induced MUC5AC expression and to explore the underlying mechanism in human bronchial epithelial cells. Firstly, the decreased cell viability, elevated release of lactate dehydrogenase (LDH), and excessively released inflammatory factors tumor necrosis factor-α (TNF-α), interleukin- 6 (IL-6), and transforming growth factor-β (TGF)-β in bronchial BEAS-2B epithelial cells induced by stimulation with LPS were significantly reversed by the introduction of Telmisartan. Secondly, the upregulated MUC5AC and downregulated suppressor of cytokine signaling 1 (SOCS1) caused by stimulation with LPS were dramatically reversed by Telmisartan. Notably, treatment with Telmisartan attenuated LPS-induced activation of nuclear factor κ-B (NF-κB). Lastly, silencing of SOCS1 abolished the protective effects of Telmisartan against LPS-induced production of MUC5AC and the activation of NF-κB. Based on these findings, we conclude that Telmisartan displayed a protective effect against LPS by improving mitochondrial function, mitigating inflammatory response, and reducing the production of mucin 5AC by regulating the SOCS1/NF-κB axis in human bronchial epithelial cells.Ling ChenJiajia XuMeiyu DengYanling LiangJinfu MaLinghui ZhangYijie WangJinping ZhangTaylor & Francis Grouparticleacute lung injurytelmisartaninflammationmucin 5ac (muc5ac)suppressors of cytokine signaling 1 (socs1)BiotechnologyTP248.13-248.65ENBioengineered, Vol 12, Iss 1, Pp 3912-3923 (2021)
institution DOAJ
collection DOAJ
language EN
topic acute lung injury
telmisartan
inflammation
mucin 5ac (muc5ac)
suppressors of cytokine signaling 1 (socs1)
Biotechnology
TP248.13-248.65
spellingShingle acute lung injury
telmisartan
inflammation
mucin 5ac (muc5ac)
suppressors of cytokine signaling 1 (socs1)
Biotechnology
TP248.13-248.65
Ling Chen
Jiajia Xu
Meiyu Deng
Yanling Liang
Jinfu Ma
Linghui Zhang
Yijie Wang
Jinping Zhang
Telmisartan mitigates lipopolysaccharide (LPS)-induced production of mucin 5AC (MUC5AC) through increasing suppressor of cytokine signaling 1 (SOCS1)
description Acute lung injury (ALI) is a serious clinical pulmonary disease. The pathogenesis of ALI is related to the excessive release of inflammatory factors and upregulation of mucin 5AC (MUC5AC). Telmisartan is a novel antihypertension agent that exerts promising anti-inflammatory effects. The purpose of this study is to investigate whether Telmisartan has a protective role in lipopolysaccharide (LPS)-induced MUC5AC expression and to explore the underlying mechanism in human bronchial epithelial cells. Firstly, the decreased cell viability, elevated release of lactate dehydrogenase (LDH), and excessively released inflammatory factors tumor necrosis factor-α (TNF-α), interleukin- 6 (IL-6), and transforming growth factor-β (TGF)-β in bronchial BEAS-2B epithelial cells induced by stimulation with LPS were significantly reversed by the introduction of Telmisartan. Secondly, the upregulated MUC5AC and downregulated suppressor of cytokine signaling 1 (SOCS1) caused by stimulation with LPS were dramatically reversed by Telmisartan. Notably, treatment with Telmisartan attenuated LPS-induced activation of nuclear factor κ-B (NF-κB). Lastly, silencing of SOCS1 abolished the protective effects of Telmisartan against LPS-induced production of MUC5AC and the activation of NF-κB. Based on these findings, we conclude that Telmisartan displayed a protective effect against LPS by improving mitochondrial function, mitigating inflammatory response, and reducing the production of mucin 5AC by regulating the SOCS1/NF-κB axis in human bronchial epithelial cells.
format article
author Ling Chen
Jiajia Xu
Meiyu Deng
Yanling Liang
Jinfu Ma
Linghui Zhang
Yijie Wang
Jinping Zhang
author_facet Ling Chen
Jiajia Xu
Meiyu Deng
Yanling Liang
Jinfu Ma
Linghui Zhang
Yijie Wang
Jinping Zhang
author_sort Ling Chen
title Telmisartan mitigates lipopolysaccharide (LPS)-induced production of mucin 5AC (MUC5AC) through increasing suppressor of cytokine signaling 1 (SOCS1)
title_short Telmisartan mitigates lipopolysaccharide (LPS)-induced production of mucin 5AC (MUC5AC) through increasing suppressor of cytokine signaling 1 (SOCS1)
title_full Telmisartan mitigates lipopolysaccharide (LPS)-induced production of mucin 5AC (MUC5AC) through increasing suppressor of cytokine signaling 1 (SOCS1)
title_fullStr Telmisartan mitigates lipopolysaccharide (LPS)-induced production of mucin 5AC (MUC5AC) through increasing suppressor of cytokine signaling 1 (SOCS1)
title_full_unstemmed Telmisartan mitigates lipopolysaccharide (LPS)-induced production of mucin 5AC (MUC5AC) through increasing suppressor of cytokine signaling 1 (SOCS1)
title_sort telmisartan mitigates lipopolysaccharide (lps)-induced production of mucin 5ac (muc5ac) through increasing suppressor of cytokine signaling 1 (socs1)
publisher Taylor & Francis Group
publishDate 2021
url https://doaj.org/article/e77a2296a10f469487182329fbab81c5
work_keys_str_mv AT lingchen telmisartanmitigateslipopolysaccharidelpsinducedproductionofmucin5acmuc5acthroughincreasingsuppressorofcytokinesignaling1socs1
AT jiajiaxu telmisartanmitigateslipopolysaccharidelpsinducedproductionofmucin5acmuc5acthroughincreasingsuppressorofcytokinesignaling1socs1
AT meiyudeng telmisartanmitigateslipopolysaccharidelpsinducedproductionofmucin5acmuc5acthroughincreasingsuppressorofcytokinesignaling1socs1
AT yanlingliang telmisartanmitigateslipopolysaccharidelpsinducedproductionofmucin5acmuc5acthroughincreasingsuppressorofcytokinesignaling1socs1
AT jinfuma telmisartanmitigateslipopolysaccharidelpsinducedproductionofmucin5acmuc5acthroughincreasingsuppressorofcytokinesignaling1socs1
AT linghuizhang telmisartanmitigateslipopolysaccharidelpsinducedproductionofmucin5acmuc5acthroughincreasingsuppressorofcytokinesignaling1socs1
AT yijiewang telmisartanmitigateslipopolysaccharidelpsinducedproductionofmucin5acmuc5acthroughincreasingsuppressorofcytokinesignaling1socs1
AT jinpingzhang telmisartanmitigateslipopolysaccharidelpsinducedproductionofmucin5acmuc5acthroughincreasingsuppressorofcytokinesignaling1socs1
_version_ 1718444747224252416